Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems

被引：123
作者：
Tsuji A. [1 ]
机构：
[1] Division of Pharmaceutical Sciences, Grad. Sch. of Nat. Sci. and Technol., Kanazawa University, Kanazawa 920-1192, Kakuma-machi
来源：
NeuroRX | 2005年 / 2卷 / 1期
关键词：
Blood-brain barrier; Drug delivery; Influx transport; Organic anions; Organic cations; Transporter;
D O I：
10.1602/neurorx.2.1.54
中图分类号：
学科分类号：
摘要：
Because of the physiological nature of the blood-brain barrier (BBB), transport of chemical compounds between blood and brain has been widely believed to occur by means of passive diffusion, depending upon the lipophilicity of the compounds. However, discrepancies exist between the lipophilicity and apparent BBB permeation properties in many cases, and these discrepancies can be ascribed to the existence of multiple mechanisms of drug transport through the BBB. Molecular identification and functional analysis of influx transport proteins (from blood to brain) and efflux transport proteins (from brain to blood) have progressed rapidly. Therefore, the BBB is now considered to be a dynamic interface that controls the influx and efflux of a wide variety of substances, including endogenous nutrients and exogenous compounds such as drugs, to maintain a favorable environment for the CNS. This review focuses on the role of transport systems in the uptake of xenobiotics, including organic anionic/cationic and neutral drugs, across the BBB into the brain, as well as on strategies to increase drug delivery into the brain by blocking efflux transport protein function, or to reduce CNS side effects by modulating BBB transport processes.
引用
收藏
页码：54 / 62
页数：8
相关论文
共 87 条
[1]  
Smith Q.R., Stoll J., Blood-brain barrier amino acid transport, Introduction to the Blood-brain Barrier, pp. 188-197, (1998)
[2]  
Christensen H.N., Role of amino acid transport and countertransport in nutrition and metabolism, Physiol Rev, 70, pp. 43-77, (1990)
[3]  
Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., Anderson J.L., The "ON-OFF" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport, N Engl J Med, 310, pp. 483-488, (1984)
[4]  
Kanai Y., Segawa H., Miyamoto K., Uchino H., Takeda E., Endou H., Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98), J Biol Chem, 273, pp. 23629-23632, (1998)
[5]  
Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J., Shoemaker C.B., Et al., Amino acid transport by heterodimers of 4F2hc/CD98 and members of a permease family, Nature, 395, pp. 288-291, (1998)
[6]  
Boado R.J., Li J.Y., Nagaya M., Zhang C., Pardridge W.M., Selective expression of the large neutral amino acid transporter at the blood-brain barrier, Proc Natl Acad Sci USA, 12, 96, pp. 12079-12084, (1999)
[7]  
Boado R.J., Li J.Y., Pardridge W.M., Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234, J Neurochem, 84, pp. 1322-1323, (2003)
[8]  
Pineda M., Fernandez E., Torrents D., Estevez R., Lopez C., Camps M., Et al., Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids, J Biol Chem, 274, pp. 19738-19744, (1999)
[9]  
Segawa H., Fukasawa Y., Miyamoto K., Takeda E., Endou H., Kanai Identification and functional characterization of a Na <sup>+</sup>-independent neutral amino acid transporter with broad substrate selectivity, J Biol Chem, 274, pp. 19745-19751, (1999)
[10]  
Kido Y., Tamai I., Uchino H., Sai Y., Suzuki F., Tsuji A., Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier, J Pharm Pharmcol, 53, pp. 497-503, (2001)
123456789